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Abstract
Background: Tuberculous meningitis is the most severe form of tuberculosis. Mortality for untreated tuberculous
meningitis is 100%. Despite the introduction of antibiotic treatment for tuberculosis the mortality rate for
tuberculous meningitis remains high; approximately 25% for HIV-negative and 67% for HIV positive patients with
most deaths occurring within one month of starting therapy. The high mortality rate in tuberculous meningitis
reflects the severity of the condition but also the poor antibacterial activity of current treatment regimes and
relatively poor penetration of these drugs into the central nervous system. Improving the antitubercular activity in
the central nervous system of current therapy may help improve outcomes. Increasing the dose of rifampicin, a key
drug with known poor cerebrospinal fluid penetration may lead to higher drug levels at the site of infection and
may improve survival. Of the second generation fluoroquinolones, levofloxacin may have the optimal
pharmacological features including cerebrospinal fluid penetration, with a ratio of Area Under the Curve (AUC) in
cerebrospinal fluid to AUC in plasma of >75% and strong bactericidal activity against Mycobacterium tuberculosis.
We propose a randomized controlled trial to assess the efficacy of an intensified anti-tubercular treatment regimen
in tuberculous meningitis patients, comparing current standard tuberculous meningitis treatment regimens with
standard treatment intensified with high-dose rifampicin and additional levofloxacin.
Methods/Design: A randomized, double blind, placebo-controlled trial with two parallel arms, comparing standard
Vietnamese national guideline treatment for tuberculous meningitis with standard treatment plus an increased
dose of rifampicin (to 15 mg/kg/day total) and additional levofloxacin. The study will include 750 patients (375 per
treatment group) including a minimum of 350 HIV-positive patients. The calculation assumes an overall mortality of
40% vs. 30% in the two arms, respectively (corresponding to a target hazard ratio of 0.7), a power of 80% and a
two-sided significance level of 5%. Randomization ratio is 1:1. The primary endpoint is overall survival, i.e. time from
randomization to death during a follow-up period of 9 months. Secondary endpoints are: neurological disability at
9 months, time to new neurological event or death, time to new or recurrent AIDS-defining illness or death (in
HIV-positive patients only), severe adverse events, and rate of treatment interruption for adverse events.
Discussion: Currently very few options are available for the treatment of TBM and the mortality rate remains
unacceptably high with severe disabilities seen in many of the survivors. This trial is based on the hypothesis that
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reproduction in any medium, provided the original work is properly cited.current anti-mycobacterial treatment schedules for TBM are not potent enough and that outcomes will be
improved by increasing the CSF penetrating power of this regimen by optimising dosage and using additional
drugs with better CSF penetration.
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Background
Driven in part by the HIV epidemic, tuberculosis (TB) is
a major global health problem. Of all the syndromes
caused by Mycobacterium tuberculosis (Mtb), tubercu-
lous meningitis (TBM) is the most severe. Almost all
patients with untreated TBM die. Since the introduction
of antibiotic treatment with streptomycin for TB in the
1950’s the death rate has declined [1]. However morbid-
ity and mortality overall are still high. In Vietnam the
death rate in HIV negative patients treated according to
current guidelines is 25%, and a further 30% of patients
suffer long term neurological sequelae [2]. 50% of adult
patients who are admitted with TB meningitis in Ho
Chi Minh City are HIV positive. HIV significantly wor-
sens outcome, with a mortality rate of 67% [3]. In our
previous studies, the majority (75%) of deaths occurred
within 1 month of starting treatment, and almost all
deaths occurred within 6 months [3]. Across the globe
similar high rates of mortality and disability are reported
for TBM [4]. Although TBM predominantly occurs in
developing countries, 320 TBM cases were reported in
the UK in 2007 making it one of the three leading
causes of meningitis in the UK. These numbers are
likely to rise, due to the global increase of drug resistant
TB, increasing use of immunosuppressive therapies, and
the HIV epidemic. Along with increased awareness and
vigilance for the disease, it is of the utmost importance
to improve treatment for TBM based on sound scientific
evidence.
Pathogenesis of TBM
The exact pathogenesis is still largely unknown and cur-
rent knowledge is based on original pathological studies
performed in the early 1930’sb yR i c ha n dM c C o r d o c k
w h op o s t u l a t e dt h a tt h ed e v e l o p m e n to fT B Mi sat w o
s t e pp r o c e s s[ 1 ] .T h ef i r s ts t e pi sb e l i e v e dt ob eas h o r t
bacteraemia following pulmonary infection that enables
the mycobacteria to seed elsewhere in the body, includ-
ing the meninges and brain parenchyma. Small foci are
believed to form subpially or subependymally, the so
called Rich foci. The second step is the rupture of these
foci in the subarachnoid space, causing the onset of
meningitis. Three general processes are thought to
cause the subsequent neurological pathology; adhesion
formation, obliterative vasculitis, and encephalitis or
myelitis. Immunopathology of TBM is still poorly
understood. As a result of a large randomized controlled
trial in Vietnam [2], guidelines now recommend all
patients with TBM should receive corticosteroids. This
trial showed a 31% reduction in risk of death. TB treat-
ment is complicated by a significant risk of adverse
events, in particular liver toxicity [5]. In the patient
group receiving dexamethasone there was a significantly
lower incidence of adverse events compared with pla-
cebo. Even though adjunctive immunomodulatory treat-
ment has a beneficial impact on outcome, mortality is
still high, especially for the intermediate and high grade
severity groups (MRC grade 2 and 3) and HIV
co-infected patients. The host-response must be supple-
mented with appropriate anti-mycobacterial agents in
order to facilitate rapid bacterial clearing and prevent a
cascade of intracerebral events that will lead to clinical
deterioration.
Treatment of TBM
There is a lack of good quality evidence on TBM treat-
ment, in particular for the anti-tubercular chemotherapy
regimens. In the past decades, no randomized controlled
trials have been published which compared different
anti-tubercular regimens and there are no good quality
cohort studies. Treatment schedules for TBM globally
are not uniform and are mostly extrapolated from those
used for pulmonary TB. The National Institute for
Health and Clinical Excellence UK (NICE) has published
guidelines for the UK in collaboration with the British
Thoracic Society (BTS) in 2006, acknowledging the lack
of evidence NICE classify the recommendation as Level
4 which indicates a weak evidence-base.
The current treatment guidelines for TBM in Vietnam
recommend treatment in the intensive phase with rifam-
picin (10 mg/kg max 750 mg/day), isoniazid (5 mg/kg,
max 300 mg/day), pyrazinamide (25 mg/kg, max 2 g/day)
and streptomycin (20 mg/kg, max 1 g/day) for 3 months.
All drugs are given orally once daily, with the exception
of streptomycin which is administered intra-muscularly.
This is followed by rifampicin and isoniazid for 6 months
in the consolidation phase. In HIV-positive patients,
streptomycin is replaced with ethambutol (15-20 mg/kg,
max 1.2 g/day). However the variability of CSF penetra-
tion of the different first-line TB-drugs may warrant a
need for adjustment of these regimens accordingly. In
particular, the penetration of rifampicin, the key drug, is
poor, as is that of ethambutol [6-10]. The mortality rate
of TBM patients may reflect both poor antibacterial
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tion of these drugs into the central nervous system. For
HIV patients the excess death rate may be a reflection of
even less efficient uptake of antimycobacterial drugs due
to malabsorption and subsequent low drug levels [9-11],
combined with a severely impaired immune system.
Improving the sterilising power of current therapy may
result in improved outcomes of all TBM patients.
We propose a randomised placebo controlled trial to
test this hypothesis in patients with TB meningitis. The
study will compare standard anti-tuberculous treatment
with anti-tuberculous treatment intensified with high
dose rifampicin and levofloxacin.
High Dose Rifampicin for TBM
Rifampicin is a semisynthetic derivative of rifamycin and is
a key drug in the treatment of all forms of TB, demon-
strated by the fact that in tuberculous meningitis resistance
to this drug is associated with high rates of relapse and
death [12]. Rifampicin is used throughout the whole of the
9 month treatment period in TBM. The recommended
dose is 10 mg/kg/day. Dosage is administered according to
weight categories. It is not recommended to divide tablets
and hence many patients in these weight categories in fact
receive less than the recommended 10 mg/kg.
Rifampicin penetrates well into cells, and is active
against intra-cellular bacteria, but CSF concentrations
are reported to be low [13-15]. There are few data com-
p a r i n gt h eA r e aU n d e rt h eC u r v e( A U C )i nt h ec e r e -
brospinal fluid and plasma compartments [AUCc/
AUCp], but the ratio is probably in the order of 10-20%.
Penetration may be influenced by the level of damage to
the blood brain barrier and the serum protein binding
of rifampicin which approaches 80% [14]. The therapeu-
tic range of rifampicin lies between 8 - 24 μg/ml and
levels below 4 μr/ml are considered very low [7,9]. Huge
inter-individual variation in metabolism and rifampicin
drug-levels have been reported, with worrying numbers
of patients with low to very low levels. HIV infection
has been associated with even lower plasma levels of
Rifampicin [10,11]. Consequently CSF levels are
expected to be in the low or very low ranges.
Recently an Indonesian study has been published con-
cluding that a dose increase from 10 to 13 mg/kg/day is
associated with a 65% increase in mean plasma AUC0-24 h
and 49% increase in plasma Cmax without a significant
increase in the rate of serious adverse events [16,17]. This
study was not powered for outcome, but the increase in
the drug levels in the CSF associated with a relatively
small increase in the doses are fascinating and may be of
clinical importance for TBM patients.
Rifampicin is relatively non-toxic. The most noticeable
side effect is red staining of body secretions, also known
as the “red man syndrome” [15]. Other side effects
include rash, flushing and gastrointestinal disturbances
(usually mild). Drug-induced hepatitis (DIH) is a well
recognised side-effect of TB treatment, with a frequency
of between 5 and 33% [5]. The drugs most usually
implicated are isoniazid and pyrazinamide. However,
transient elevation of transaminases (and less commonly
bilirubin) is reported with rifampicin use. DIH usually
responds well to treatment interruption. A gradual
sequential re-introduction of each drug is usually toler-
ated without recurrence of hepatitis [5].
Based on the data presented in this section we pro-
pose an increased dose of rifampicin of 15 mg/kg for
patients with TBM, to increase serum levels and we
anticipate increase levels of rifampicin at the site of
infection. With this strategy we aim to improve the ster-
ilising power of the anti tubercular regimen in the brain.
Levofloxacin for TBM
Of the anti-tubercular reserve drugs, fluoroquinolones,
in particular levofloxacin, are an attractive candidate in
the treatment of TBM. Especially the later generation
drugs such as levofloxacin, moxifloxacin and gatifloxacin
have improved in vitro activity, and there is evidence of
good sterilising activity in sputum in pulmonary TB
[18,19]. Despite demonstration of in vitro activity of var-
ious drugs against Mtb, there has been little progress in
drug development or assessment of alternative anti-
mycobacterial treatment regimes in TBM [20]. Trials in
pulmonary TB however, have demonstrated the safety of
prolonged treatment with fluoroquinolones [21,22].
Fluoroquinolones are an attractive option for the treat-
ment of TBM because of their demonstrable in vitro
activity, tolerability, good bioavailability and ease of
administration [23-37]. Our centre recently completed a
pharmacokinetic study comparing oral ciprofloxacin
(750 mg/12 hours), levofloxacin (500 mg/12 hours) or
gatifloxacin (400 mg/24 hours) for the first 60 days in
patients with TBM, and examining their pharmacokinetic
interaction with rifampicin. We found levofloxacin to
have excellent CSF penetration, with AUCc/AUCp = 75%.
This compared favourably with gatifloxacin (35%) and
ciprofloxacin (14%). Of the second generation fluoroqui-
nolones, levofloxacin has the greatest Early Bactericidal
Activity (EBA), comparable to that of isoniazid. The MIC
of drug sensitive isolates is in the order of 0.25 - 1 μg/ml
[34,38]. Plasma levels of levofloxacin in Vietnamese
patients are comfortably in excess of this, with AUC0-12
of 80 mg/hr/L (G. Thwaites Personal Communication).
Fluoroquinolone resistance has been identified in
strains from Vietnam, but currently is rare in TBM
cases (<1%) and less frequent than rifampicin resistance
(M. Caws Personal Communication). Levofloxacin has
performed well in human studies using surrogate mar-
kers of efficacy such as EBA (rate of fall of colony
Heemskerk et al. Trials 2011, 12:25
http://www.trialsjournal.com/content/12/1/25
Page 3 of 11forming units in sputum) [18]. This is probably a reflec-
tion of its favourable pharmacokinetic profile resulting
in high plasma and intracellular concentrations.
Levofloxacin has the advantages of a favourable toxi-
city profile, affordable cost and an extensive amount of
available safety data from clinical trials examining its
prolonged use in pulmonary TB. We propose levofloxa-
cin as an additional drug in the highly active treatment
arm combined with a high dose of rifampicin in this
randomised placebo controlled trial.
Hypothesis
Current antimycobacterial regimes are not potent enough
to treat TBM effectively, as most of the antimycobacterial
drugs have very low cerebrospinal fluid penetration.
Increasing levels of effective anti-mycobacterial drugs in
the cerebrospinal fluid and hence at the site of infection
will we hope improve treatment outcome.
Aims
The primary aim of this study will be to reduce mortality
by intensifying the induction phase of anti-tuberculous
treatment of TBM. Secondary aims are to assess the
effect on morbidity and disability of intensifying standard




This is a randomized, double blind, placebo-controlled
trial with two parallel arms, comparing standard anti-
tubercular treatment for tuberculous meningitis (accord-
ing to national guidelines) with standard treatment plus
an increased dose of rifampicin and additional levofloxa-
cin. We aim to enhance the antimycobacterial efficacy
of current treatment for TB meningitis in Vietnam by
adding levofloxacin 20 mg/kg/day to the intensive phase
of treatment and increasing the dose of rifampicin to
15 mg/kg/day during the intensive phase of treatment
for the duration of 2 months (Figure 1)
Inclusion and exclusion criteria
All adult patients (aged ≥ 18 years) with a clinical diag-
nosis of TBM (Additional File 1) presenting to the Hos-
pital for Tropical Diseases (HTD), HCMC, or Pham
Ngoc Thach Hospital (PNT), HCMC, will be eligible to
enter the study. Exclusion criteria are: a positive CSF
Gram or India Ink stain, pregnancy, known hypersensi-
tivity/intolerance to fluoroquinolones or rifampicin,
creatinine >3 ULN, laboratory contraindications to anti-
tuberculous therapy (bilirubin > 2.5 × ULN, AST or
ALT > 5 × ULN), diagnosis of multi-drug resistant
TBM or lack of informed consent
Primary endpoint
The primary endpoint will be overall survival, i.e. time
from randomization to death during a follow-up period
of 9 months. Survivors will be censored at the date they
were last known to be alive (i.e. date of last follow-up
visit, loss to follow-up or withdrawal).
Secondary endpoints
The secondary endpoints are:
a) neurological disability at 9 months, assessed using
the “two simple questions” and Rankin score (Additional
File 2).
b) time to new neurological events or death (Neurolo-
gical events are defined as: any of the following adverse
events: cerebellar symptoms, coma, hemiplegia, neurolo-
gical deterioration, paraplegia, seizures, cerebral hernia-
tion or cranial nerve palsy or a fall in Glasgow coma
score by ≥ 2 points for ≥ 2 days from highest previously
recorded Glasgow coma score).
c) any grade 3 or 4 adverse event (Additional File 3).
d) rate of treatment interruption for adverse events.
e) the rates of asymptomatic transaminitis and symp-
tomatic hepatitis.
f) time to new or recurrent AIDS defining illness or
death (in HIV positive patients only).
g) time to undetectable viral load (in HIV positive
patients only).
h) CD4 count at completion of therapy (in HIV posi-
tive patients only).
Randomization procedure
Randomization will be 1:1 and patients will be stratified
according to hospital site (HTD and PNT), HIV status
and TBM disease severity at presentation (TBM severity
will be graded according to the modified MRC system,
Additional File 4). Enrolment logs specific to site, HIV
positivity and severity of TBM will be used to assign
patients to the next available sequential number within
the appropriate stratification group. The assigned num-
ber will correspond to two pre-packaged bottles which
contain a 2 month supply of additional doses of rifampi-
cin and levofloxacin or visually matched placebos of
each. Bottles will be prepared centrally by an unblinded
study pharmacist and distributed to the sites in batches
as required. Only two central study pharmacists who
will hold the master randomization list will know the
contents of each bottle. This list will be accessed only in
the case of emergency unblinding authorized by an
investigator as per standard operating procedures.
Within strata, we will use block randomization with
variable block size. Stratified randomization will ensure
that almost equal numbers of patients with equivalent
prognosis are included in the two treatment arms.
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For each group, tablets of intensified treatment or pla-
cebo will be placed in bottles in coded sealed packages,
which are labeled with the randomization number of
the patient. Drug appearance and administration
schedules will be identical to maintain blinding
amongst the attending physicians and nurses. The
admitting physician will be responsible for ensuring
the patient satisfies the entry criteria, completes
informed consent and starts a study drug treatment
                                HTD or PNT hospital (stratification) 
      
CONSENT 
Inclusion Criteria 
Age t 15 years 
Clinical diagnosis of TBM 
Exclusion criteria 
Estimated GFR < 40ml/min 
Bilirubin > 2.5 x ULN 
AST or ALT > 5 x ULN 
Positive CSF Gram or India Ink stain 
Pregnancy 
Lack of consent 
HIV test (stratification)
TBM grade (stratification)
Grade 1 = GCS 15 with no focal neurology or
Grade II = GCS 11-14 or GCS 15 with focal neurology or
Grade III = GCS d 10 
Experimental Treatment 
Randomised to 






Or Identical Placebos    2 months 
Plus Backbone TB treatment 
Drug Dose
Isoniazid (H)  5mg/kg od po, max 300mg /day 
Rifampicin (R)  10mg/kg od po 
Pyrazinamide (Z)  25mg/kg od po, max 2g/day 
Ethambutol (E) and/or  15 - 20mg/kg od po, max 1.2g/day 
Streptomycin (S)  20mg/kg od im, max 1g/day 
After 3 months, stop ZE/S and continue RH for 6 months 
Plus Dexamethasone treatment 
Grade 1 TBM  Grades 2 and 3 TBM 
Week 1  0.3 mg/kg iv  0.4 mg/kg iv 
Week 2  0.2 mg/kg iv  0.3 mg/kg iv 
Week 3  0.1 mg/kg iv  0.2 mg/kg iv 
Week 4  3.0mg total/day po  0.1 mg/kg iv 
Week 5  2.0mg total/day po  4.0mg total/day po 
Week 6  1.0mg total/day po  3.0mg total/day po 
Week 7    2.0 mg total/day po 
Week 8    1.0 mg total/day po 
For HIV-patients: HIV treatment 
According to national guidelines. Deferred until 8 weeks, unless already on treatment upon admission 
Follow-up Weekly (0-2 months), Monthly (3-9 months) 
Figure 1 Trial flow diagram.
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patient case record forms (CRFs).
Additional treatment for all TBM patients
All patients will receive backbone treatment with stan-
dard antituberculous therapy (Additional File 5) and
adjunctive dexamethasone (Additional File 6) on study
entry, according to Pham Ngoc Thach Hospital and Viet-
namese National TB Programme guidelines. All patients
receiving isoniazid will also receive pyridoxine (vitamin
B6). Patients, who develop TBM while on treatment for
pulmonary TB, will be eligible to enter the study. Accord-
ing to Vietnamese hospital guidelines, these patients will
receive TBM-treatment with 5 first line TB-drugs
(SRHZE) which will be the “backbone” or standard TB
treatment. If patients consent to take part in the trial,
they will be randomized to intensified TB treatment or
placebo as described previously. If the patient is coma-
tose, the drugs can be given by nasogastric tube.
Second-line antituberculous therapy
Patients with a definite or clinical diagnosis of multi-
drug resistant (MDR) TBM will be excluded from the
trial and referred to the MDR-TBM department for sec-
ond- line MDR treatment according to NTP guidelines.
Change to: Patients who have been randomized and are
subsequently diagnosed with MDR-TB will be referred
for second-line therapy according to Vietnamese guide-
lines. They will continue to be followed up in the study
and included in the ITT analysis.
Anti-retroviral therapy
Antiretroviral therapy will be provided for HIV infected
patients within the current Vietnamese guidelines. Anti-
retroviral therapy is available free of charge through the
US Government PEPFAR programme for in-patients
with life-threatening opportunistic infections from
2 weeks after admission. HIV positive patients will be
referred to the HIV Outpatient Clinic (OPC). To ensure
that treatment naïve HIV-positive patients receive ARV
treatment at 8 weeks and continue their treatment,
patients will be enrolled either at the hospital OPC or
through local specialized OPC services, following stan-
dard local practice. For ARV-treatment naïve patients,
ARV therapy will be initiated after 8 weeks of TB ther-
apy. This is consistent with the results of the recent trial
of immediate or deferred antiretroviral therapy in TB
meningitis, carried out by our group and consistent with
local practice guidelines (E. Torok Personal Communi-
cation). There are currently 4 different treatment sche-
dules for first line ARV treatment in Vietnam, all
containing 2 NRTI’sa n d1N N R T I .P a t i e n t sa l r e a d y
receiving ARVs at the time of diagnosis of TBM will
continue ARV therapy. The majority of patients will be
on schedules containing nevirapine (NVP). According to
Vietnamese guidelines NVP will be changed to efavirenz
for HIV positive patients that require a TB-regimen
containing rifampicin.
Reports show good clinical outcome for patients on a
600 mg dose of efavirenz who are on TB-regimens con-
taining rifampicin [39]. Accordingly and following
National treatment guidelines, the dose of efavirenz will
not be increased for patients on TB-regimens containing
rifampicin. Second line ARV treatment is rarely pre-
scribed in Vietnam. Very few patients will have a PI in
their treatment schedule. Decisions on dose or schedule
adjustments for these patients will be made on an indi-
vidual basis, following the National guidelines. Liver
function tests will be monitored in all patients.
Prophylaxis for opportunistic infections (for HIV positive
patients)
Patients will receive prophylaxis for opportunistic infec-
tions according to Vietnamese national guidelines. If the
CD4 count is less than 200 cells/uL, patients will receive
prophylaxis against Pneumocystis jirovecii pneumonia and
cerebral toxoplasmosis with cotrimoxazole 960 mg/day.
Data on concomitant medications
At each visit, information on other medications, includ-
ing start dates and indications, will be documented in
the case record forms.
Data collection
Baseline evaluation
On admission all patients will have a full clinical assess-
ment and examination to determine TBM MRC grade
(Additional File 4), and assess any neurological symp-
toms and signs. The following laboratory tests will be
performed at study entry: haematology (full blood
count), biochemistry (total protein, albumin, creatinine
and liver function tests), cerebrospinal fluid (cell count,
protein, glucose, lactate, Gram stain, Ziehl - Neelsen
(ZN) stain, India Ink stain, cryptococcal antigen, bacter-
ial and mycobacterial culture), HIV test. Additional tests
for HIV positive patients will include immunology (CD4
count) and virology (confirmatory HIV test, plasma
HIV-1 RNA, HbsAg, HBV DNA, HCV Ab test, HCV
RNA). A baseline chest radiograph will be performed
for all patients. A CT or MRI brain scan will be per-
formed if there is evidence of raised intracranial pres-
sure or focal neurological abnormalities.
In-patient monitoring
Patients will have daily review until discharge from hos-
pital at 2 months (this period may be adjusted according
to clinical findings) for neurological, drug-related
adverse events (Additional File 3) and new or recurrent
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In-patients will have weekly routine laboratory monitoring
of haematology (full blood count) and biochemistry (crea-
tinine and liver function tests). Cerebrospinal fluid analysis
will be done routinely according to local guidelines at
4 and 8 weeks.
A subgroup of patients recruited to the pharmacoki-
netics study will have additional blood and CSF samples
taken. Other investigations may be performed if clini-
cally indicated. Uniform management of patients and
recording of data will be ensured by the principal inves-
tigator who will make a daily round of all study partici-
pants. Following discharge, patients will be followed up
as part of the National Tuberculosis Programme. Formal
outpatient review will occur monthly until the comple-
tion of treatment, at 9 months.
Out-patient monitoring
Out-patients will pay monthly visits to the out-patient
department (OPD) for clinical evaluation and laboratory
monitoring until completion of treatment at 9 months.
Haematology (full blood count) and biochemistry (crea-
tinine, liver function tests) will be checked monthly.
Final cerebrospinal fluid analysis will be at 9 months.
HIV positive patients will have additional samples taken
for immunology (CD4, CD8) and virology (plasma HIV-
1 RNA) every 3 months until the end of treatment.
A subgroup of HIV positive patients who started ARV-
treatment at week 8 of TBM-treatment will have an
additional cerebrospinal fluid analysis at the 3 month
OPD-visit.
Imaging
Chest and brain imaging will be performed as clinically
indicated - i.e. in the event of pulmonary or neurological
deterioration.
Clinical trial specimens
All clinical trial specimens will be labeled with the
patient’s trial number. Samples will be transferred to the
laboratories at the Hospital for Tropical Diseases and
Pham Ngoc Thach Hospital for initial processing. Inves-
tigation results will be issued to the investigators in a
timely manner and a hard copy of the results will be
retained in the laboratory for verification. Samples will
be stored securely in freezers at the Hospital for Tropi-
cal Diseases and Pham Ngoc Thach Hospital prior to
transfer to the Oxford University Clinical Research Unit
for further investigations and long term storage.
Management of adverse events and toxicities
Management of antituberculous toxicity
A symptom checklist will be used to determine clinical
toxicity. Routine laboratory tests will be performed
weekly as an inpatient and monthly as an outpatient.
Clinicians may also request additional tests if clinically
indicated. Common side effects of first-line TB-drugs
are given in Additional File 3). Therapy may need to be
interrupted for severe (grade 3 or 4) adverse events.
Once clinical and laboratory features resolve, drugs may
be reintroduced sequentially. Details of management are
given in Additional Files 7,8,9.
Reporting adverse events
According to the ICH Guidelines for Clinical Safety
Data Management: definitions and Standards for Expe-
dited Reporting (1994), a serious adverse event (SAE) is
defined as “any untoward medical occurrence that a)
results in death, b) is life threatening, c) requires
unplanned inpatient hospitalization or prolongation of
existing hospitalization, d) results in persistent or signifi-
cant disability/incapacity or is a congenital anomaly/
birth defect, e) any other important medical condition,
which, although not included in the above, may jeopar-
dize the subject and may require medical or surgical
intervention to prevent one of the outcomes listed.”
If the patient dies or experiences an adverse event
(serious, grade 3 or 4, or one leading to modification of
treatment, see Additional File 3 Common Toxicity Cri-
teria) the investigator should inform the principal inves-
tigator as soon as possible and complete the specific
case report form. When applicable, adverse events will
be treated as per the management guidelines in Appen-
dix 2.0. All SAEs will be recorded on the SAE form and
reported to the principal investigator, the Oxford Tropi-
cal Research Ethics Board and the Ethical Committee of
the Ministry of Health Vietnam within 72 hours of the
event. Unblinded adverse event and mortality summaries
will be reviewed by the trial’s independent Data and
Safety Monitoring Committee at regular time points
(see section “ethical issues” for details.) If there is a pro-
tocol violation for any reason this will be fully recorded.
Protocol violations which affect patient safety will be
reported to the Oxford Tropical Research Ethics Board
and the Ethical Committee of the Ministry of Health
Vietnam.
Statistical considerations
Sample size and power calculations
The trial is powered for the primary endpoint, i.e. overall
survival during the 9 month follow-up period. Based on
previous publications from our research group, the
9-month mortality in the control arm is expected to be
60-65% in HIV-positive and around 25% in HIV-negative
TBM patients [2]. Approximately 50% of TBM patients
in the participating hospitals are HIV-positive; we there-
fore expect an overall 9-month mortality rate of around
40% in the control arm of our trial. An absolute risk
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due to intensified treatment was judged as both realistic
and clinically relevant.
Assuming proportional hazards, these mortality esti-
mates translate into a hazard ratio of 0.7 [= log(1-0.3)/
log(1-0.4)], i.e. a 30% risk reduction due to intensified
treatment on the hazard ratio scale. Based on Schoen-
feld’s formula, a total of 247 deaths are required to
detect a hazard ratio of 0.7 based on a two-sided test at
the 5% significance level with 80% power; assuming an
overall mortality rate of 35% in the trial, this translates
into 706 required patients. In order to account for
potential deviations from our assumptions and losses to
follow-up, a safety margin of 6% was added to this num-
ber leading to a total sample size of 750 patients (375
per treatment group).
HIV-positive TBM patients with a very high mortality
are a particularly important subgroup of our study
population and we aimed to have sufficient power to
also detect a benefit in this subgroup of patients alone.
If intensified treatment reduces 9-month mortality by
15% in HIV-positive patients (from 65% to 50%), corre-
sponding to a hazard ration of 0.67, a total of 196
deaths in HIV-positive patients are required to detect
this difference with 80% power; approximately 350 HIV-
positive patients are necessary to observe 196 deaths
during follow-up.
To guarantee both sufficient power in the subgroup of
HIV-positive TBM patients and a sufficiently high event
rate in the total population, the trial will continue
recruitment until both a total of 750 patients and a
minimum of 350 HIV-positive patients have been
recruited.
Primary and secondary endpoint analysis
The primary endpoint of this trial is overall survival, i.e.
time from randomization to death, during the entire fol-
low-up period of 9 months. Overall survival will be ana-
lyzed with a log-rank test stratified by HIV status
(positive/negative) and TBM disease severity at presen-
tation (modified MRC grade I, II or III). Kaplan-Meier
plots and explicit survival estimates at 3, 6 and 9
months of follow-up will also be calculated for the full
populations and in the subgroups defined by HIV status
and TBM disease severity separately.
In a second stage, overall survival will be modeled
using the Cox proportional hazards regression model
and the following covariates (in addition to the treat-
ment group): TBM disease severity (grade I, II, or III),
HIV status (positive/negative), participating hospital
(PNT/HTD), previous TB treatment (yes/no), drug resis-
tance (drug sensitive/MDR-TB/Isoniazid resistant non-
MDR). A separate analysis for HIV positive patients
only will be performed which will include prior
antiretroviral therapy (yes/no), CD4 cell count and
log10-HIV viral load at baseline as additional covariates.
The homogeneity of the treatment effect on overall
survival in the subgroups defined by TBM grade (I, II,
or III), HIV status (positive/negative), prior TBM treat-
ment (yes/no), drug resistance (drug sensitive/MDR-TB/
isoniazid resistant non-MDR) respectively, will be exam-
ined and tested using tests of interaction between treat-
ment and the grouping variable.
For the secondary endpoints concerning neurological
disability, the disability score at month 3, 6, and 9 of fol-
low-up is defined as the higher (worse) of the “simple
question” and the Rankin score assessed at that time
point as previously described [2]. Disability score will be
defined as 4 (worst outcome) if the patient died prior to
the respective time point. The score of primary interest is
the month 9 score which will be compared between the
two arms with the generalized Cochran-Mantel-Haenzsel
test as described in Mantel’s generalized statistics [40]
taking into account that the disability score is ordinal.
The test will be stratified by HIV status and TBM disease
severity at presentation. Patients lost to follow up will be
analyzed according to their last recorded disability status.
If the rate of patients lost to follow-up exceeds 10%, we
will also perform an alternative analysis based on multi-
ple imputation of missing values.
Time-to-event endpoints, i.e. time to new neurological
event or death and time to new or recurrent AIDS
defining illness or death (in HIV positive patients only),
will be analyzed with a log-rank test, Kaplan-Meier
curves and Cox regression models as described for the
primary endpoint above.
All reported serious and grade 3&4 adverse reactions
will be listed; their overall frequencies and the rate of
treatment interruptions due to adverse events will be
compared between the two treatment groups using a
generalized Cochran-Mantel-Haenszel test stratified by
HIV status and TBM disease severity at presentation.
Analysis populations
All patients will be analyzed in the primary analysis
according to their randomization arm (intention-to-
treat, ITT). The primary endpoint, overall survival, will
in addition be analyzed on the per-protocol (PP) popula-
tion which excluded the following patients: patients with
a final diagnosis other than TBM, major protocol viola-
tions and those receiving less than 2 months of adminis-




This protocol, the patient information sheet, the patient
consent form has been reviewed and approved by the
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and the Institutional Review Boards of the Hospital for
Tropical Diseases and Pham Ngoc Thach Hospital. The
study and study materials have also been submitted for
approval by the Ethical Committee of the Ministry of
Health Vietnam.
Informed consent and information sheet
A patient cannot enter the trial without informed
consent.
Written informed consent will be sought for all
patients entering the trial. When written consent is not
possible verbal consent will be considered acceptable in
the presence of a witness who can attest to the accurate
reading of the informed consent form and the agree-
ment of the patient. The doctor entering the patient
into the trial is responsible for obtaining informed con-
sent. If the patient is unconscious, the consent of the
relatives or family members is acceptable. If there are
no relatives, the consent of two independent physicians
will be considered acceptable. In this case consent from
the patient will be sought as soon as the patient regains
the ability to give or refuse consent.
Withdrawal from the trial
Patients may voluntarily withdraw from the trial for any
reason. If this occurs, the trial researchers are under no
obligation to provide treatment. The withdrawal of the
patient from the trial will not affect their access to the
best standard of care within the national health system.
Clinical and laboratory assessment should be performed
and recorded at the time of withdrawal.
Confidentiality
A unique trial number will be assigned to each patient
entering the trial and will be used to identify all labora-
tory specimens and the case record forms. All records
will be stored securely on the wards or in the OUCRU.
Clinical information will not be released without written
permission of the patient.
Interim analysis and role of the Data and Safety
Monitoring Committee (DSMC)
An independent DSMC will oversee the trial. Interim
analyses are planned after 20 deaths have been observed,
after 6 and 12 months of recruitment and yearly there-
after until the completion of the trial. The DSMC will
be provided with unblinded summary tables of grade
3&4 and serious adverse events and an analysis of over-
all survival. These analyses will be performed by an
independent statistician not otherwise involved with the
trial.
Based on these data, the committee will make one of
the following recommendations:
￿ Continue the trial without modification
￿ Continue the trial with modification
￿ Stop the trial due to safety concerns
Unless the benefit of intensified treatment is shown
“beyond reasonable doubt” at an interim analysis, no
formal stopping for efficacy is foreseen. The Haybittle-
Peto boundary, requiring p < 0.001 at interim analysis
to consider stopping for efficacy, should be used as a
guidance. However, the DSMB recommendation should
not be based purely on statistical tables but also requires
clinical judgment. As the dissemination of preliminary
s u m m a r yd a t ac o u l di n f l u e n c et h ef u r t h e rc o n d u c to f
the trial and introduce bias, access to interim data and
results will be confidential and strictly limited to the
involved independent statistician and the monitoring
board and results (except for the recommendation) will
not be communicated to the outside and/or clinical
investigators involved in the trial.
Discussion
Currently very few options are available for the treat-
ment of TBM. There are 5 “first-line drugs” and a small
number of “second-line drugs”. With the exception of
fluoroquinolones, the second- l i n ed r u g sa r er e l a t i v e l y
toxic and apart from ethionamide, cycloserine and some
of the fluoroquinolones, penetration into the CSF is
poor. Several new agents are now in the early stages of
clinical evaluation, but will not be evaluated in treating
TBM in the immediate future. The amplification of
MDR-TB strains globally and the exceptionally high
mortality among MDR-TBM patients are worrying signs
of insufficient TB and TBM treatment globally. This
trial is based on the hypothesis that current anti-myco-
bacterial treatment schedules for TBM are not potent
enough and that outcomes will be improved by increas-
ing the CSF penetrating power of this regimen by opti-
mising dosage and using additional drugs with better
CSF penetration. We acknowledge the fact that this trial
is testing this hypothesis by essentially including two
interventions in one arm of the trial. From a clinical
point of view the main interest of this research is
improving treatment, however scientifically it would be
satisfying to know, if positive results are observed, to
which drug they can be attributed or which modifica-
tions are strictly necessary in this treatment regimen.
In order to assess the effect of either intervention
alone and the combined effect it is necessary to either
perform a series of trials or do a 2 × 2 factorial trial. In
a companion paper to the present study protocol [41]
we show that an adequately powered 2 × 2 factorial
design would require an eight-fold increase in sample
size that would transform our study protocol from what
will be the largest trial ever conducted in TBM to an
impossible study. Currently 40% of all adult patients
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mortality we argue for a pragmatic approach. The quest
for optimal treatment should no longer be postponed.
Subsequent trials to further refine the optimal treatment
can be initiated if the present working hypothesis proves
successful.
Additional material
Additional file 1: Diagnostic criteria for tuberculous meningitis.
Diagnosis and grading of tuberculous meningitis, including outcome and
disability.
Additional file 2: Outcome and disability grading.
Additional file 3: Toxicity grading and management. Table of
common toxicity criteria.
Additional file 4: Modified MRC grading for tuberculous meningitis.
Additional file 5: Standard TBM treatment. First-line antituberculous
therapy.
Additional file 6: Dexamethasone therapy.
Additional file 7: Guide to management of toxicities.
Additional file 8: Management of common adverse effects of
antituberculous medications.
Additional file 9: Reintroduction of antituberculous therapy. Based
on British Thoracic Society Guidelines for chemotherapy and
management of tuberculosis (Thorax 1998; 53: 536-548).
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